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Respiratory  syncytial  virus  (RSV)  is  a globally  prevalent  cause  of lower  respiratory  infection  in  neonates
and  infants.  Despite  its disease  burden,  a safe and  effective  RSV  vaccine  has remained  elusive.  In recent
years,  improved  understanding  of  RSV  biology  and  innovations  in  immunogen  design  has  resulted  in  the
advancement  of  multiple  vaccine  candidates  into  the  clinical  development  pipeline.  Given  the  growing
number  of  vaccines  in  clinical  trials,  the  rapid  pace  at which  they  are  being  tested,  and  the  likelihood
that  an RSV  vaccine  will  reach  the commercial  market  in  the  next  5–10  years,  consensus  and  guidance
on  clinical  development  pathways  and  licensure  routes  are  needed  now,  before  large-scale  efﬁcacy  trials
commence.  In pursuit  of  this  aim,  the  World  Health  Organization  convened  the ﬁrst  RSV vaccine  consul-
tation  in  15  years  on  the 23rd  and  24th  of  March,  2015  in  Geneva,  Switzerland.  The  meeting’s  primary
objective  was  to provide  guidance  on  clinical  endpoints  and  development  pathways  for  vaccine  trials
with  a focus  on considerations  of  low-  and  middle-income  countries.  Meeting  participants  reached  con-
sensus  on  candidate  case  deﬁnitions  for RSV  disease,  considerations  for clinical  efﬁcacy  endpoints,  and
the  clinical  development  pathway  for  active  and  passive  immunization  trials  in maternal  and  pediatric
populations.  The  strategic  focus  of  this  meeting  was  on  the  development  of  high  quality,  safe  and  efﬁ-
cacious  RSV preventive  interventions  for  global  use  and  included:  (1)  maternal/passive  immunization  to
prevent  RSV  disease  in  infants
infants  and  young  children  on
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. Introduction and objectives
Dr. Vasee Moorthy (WHO) opened the meeting with a descrip-
ion of key processes that lead to licensure, policy recommendation,
requaliﬁcation and ﬁnancing of new vaccines for use in low- and
iddle-income countries (LMICs). The WHO  plays an important
ole in setting up international standards for the quality, safety and
fﬁcacy of vaccines, developing policy recommendations, publish-
ng position papers, and assessing priority vaccines for the United
ations Prequaliﬁcation Program. The Prequaliﬁcation Program is
anaged by the WHO  and, in close cooperation with national reg-
latory agencies and partner organizations, aims to make quality
accines of priority available for the beneﬁt of those in need. Pri-
ary considerations for WHO  pre-qualiﬁcation and subsequent
nvestment by the Global Alliance for Vaccines and Immuniza-
ion (GAVI) include demonstrated efﬁcacy, product quality, safety,
mplementation feasibility, and affordability [1].
The meeting focused on the clinical development of RSV vac-
ines for use in LMICs, rather than in high-income countries
HICs), which was scheduled for a separate discussion (notably at
he US Food and Drug Administration in June 2015). Topics dis-
ussed included: (1) provision of guidance on RSV vaccine clinical
evelopment pathways to support evidence-based policy recom-
endations in LMICs; (2) RSV case deﬁnitions and vaccine efﬁcacy
ndpoints; (3) priority areas and knowledge gaps that need to
e addressed for deﬁning a roadmap to RSV vaccine licensure.
dditional considerations will also have to be given to the speciﬁ-
ation of target populations (Table 1) (i.e. pregnant women, infants,
hildren), improvement of RSV surveillance and disease burden
stimates, and standardization in the choice, methodology, and
nterpretation of laboratory assays to assess immunogenicity and
acilitate prioritization of the vaccine candidate pipeline. With
hese goals and objectives in mind, there was a program of presen-
ations and guided discussions that involved representatives from
cademia, industry, and regulatory authorities.
. Overview of RSV and vaccine development strategies
Dr. Barney Graham (US National Institutes of Health (NIH))
pened with a review of RSV pathogenesis following natural
nfection and the potential mechanism of disease enhancement
bserved in the formalin-inactivated RSV (FI-RSV) investigational
accine trials of the 1960s. The natural history of RSV disease
ollows from virus tropism for the ciliated epithelia of small bron-
hioles and type I pneumocytes of the alveoli [2]. The subsequent
mmune response results in the accumulation of mucus, sloughed
pithelium and lymphoid aggregates that obstruct the bronchioles,
hich partially explains why infants – who have narrower and
igher resistance small airways – are more prone to severe bron-
hiolitis [3]. The mechanism by which the FI-RSV vaccine caused
nhanced disease and death, however, differed from the immune
esponses and pathology associated with natural infection; as
he FI-RSV investigational vaccine induced a high titer of bind-
ng antibodies relative to the titer of functional inhibiting activity
nduced, resulting in immune complex deposition and comple-
ent activation [4–9]. Additionally, FI-RSV appeared to shift CD4+
-cell immunity to a Th2 proﬁle characteristic of allergic inﬂam-
ation [10,11]. Recent data have demonstrated that the fusion
able 1
trategic goals for RSV vaccines with a focus on global use.
RSV vaccines for maternal/passive immunization to prevent RSV disease in
infants less than 6 months of age
RSV vaccines for pediatric immunization to prevent RSV disease in infants and
young children once protection afforded by maternal immunization wanese 34 (2016) 190–197 191
glycoprotein (F) exists in both the native pre-fusion and post-fusion
conformations and that virions over time, especially when heated,
lose pre-fusion F to an irreversible conformational change to the
post-fusion state (B. Graham, personal communication). Therefore,
the processed virions lose the neutralization-sensitive epitopes
present on pre-fusion F and would elicit more post-fusion F-speciﬁc
antibodies with lower neutralizing potency than observed after
natural infection [12,13].
The design of an RSV vaccine that is both safe and effec-
tive will have to obviate the mechanism by which FI-RSV caused
harm in the past. Before embarking on human trials, the immuno-
genicity and safety of vaccine candidates should be assessed in
one or more animal models, including those that exhibit FI-RSV-
associated immunopathology. Mice are the most facile model
for documenting T cell response patterns following infection or
vaccination, manifesting illness and weight loss following high-
titer infection, and demonstrating lung pathology consistent with
vaccine-enhanced illness seen in children, particularly eosinophilia
and alveolitis. Although cotton rats do not exhibit any signs of
illness, they are more permissive to infection than mice are (espe-
cially neonates) and have more delayed viral clearance. Rats have
better standardization than mice for pathologic scoring of alveoli-
tis following FI-RSV immunization and viral challenge [14–16]. The
bovine model, though logistically more challenging and expensive
to work with, is the most analogous to RSV pathogenesis in humans.
The challenge of calves with bovine RSV may  cause nearly identical
pathology in the bronchiolar epithelium, as is observed following
natural infection with human RSV in infants [17]. Although bovine
RSV has only partial homology with human RSV, the ectodomain
of F is 90% identical and neutralizing antibodies to human RSV F
can cross-neutralize bovine RSV, allowing indirect testing of human
vaccines. Given the safety concerns of previous vaccine candidates,
evaluation of RSV vaccine candidates intended for use in antigen-
naïve infants will need to be performed in animal models to support
a rationale for why  the vaccine approach would have an acceptable
safety proﬁle in this population.
Dr. Ruth Karron (Johns Hopkins University) reviewed promis-
ing vaccine candidates entering, or already in, clinical trials. These
include more than ten candidates delivered as protein subunits,
live-attenuated viruses, or recombinant viral vectors (Fig. 1). The
primary goal of RSV vaccination is protection against RSV lower
respiratory tract illness (LRTI) in the target population, as induc-
tion of sterilizing immunity is unlikely to occur. As infants are
the priority population for both active and passive immunization,
consideration must be given to how maternal factors may  inﬂu-
ence vaccine efﬁcacy. These factors include the phenomena of
infant immune response suppression by maternal antibody and
transplacental antibody transfer in the setting of HIV infection,
hypergammaglobulinemia, or placental malaria [18,19]. Develo-
pers and regulators will also have to decide whether the guidance
used for the past few decades still applies: that only live-attenuated
viruses be used in pediatric populations and subunits or other non-
replicating vaccines are best used for maternal immunization.
Dr. Peter Collins (NIH) provided additional details on the live-
attenuated and live-vectored RSV vaccines currently in clinical
development. Live vaccines have the advantage of inducing broad
humoral and cellular immunity without requiring an adjuvant
and are not likely to cause FI-RSV enhanced disease, as they
present viral surface glycoproteins in their native conformations
[20,21]. However, because these live viruses induce immunity
through replication, they must be highly attenuated [22]. Dr. Collins
presented vaccines based on three live attenuated RSV strains,
two of which have recently completed phase I clinical trials in
RSV seronegative infants. Surveillance data following administra-
tion of one candidate suggests that immunization primes for an
anamnestic RSV neutralizing antibody response. More than one
192 K. Modjarrad et al. / Vaccine 34 (2016) 190–197
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ive-attenuated vaccine candidate is likely to be advanced further
or clinical testing in larger and more diverse populations.
. RSV epidemiology: Burden estimates and knowledge
aps
Drs. Janet Englund (University of Washington), Harish Nair (Cen-
re for Population Health Sciences, University of Edinburgh) and
ames Nokes (KEMRI Wellcome Trust/Warwick University) each
resented on the progress and challenges in measuring RSV inci-
ence, disease burden, and mortality in LMICs. One complicating
actor is the variation in seasonality of disease burden within and
cross global regions. While mid-winter epidemics tend to occur
n temperate zones, seasonality is less pronounced and occasion-
lly absent in tropical and arctic climates [23–25]. These ﬁndings
ome with the caveat that data from LMICs, particularly in infants
ess than six months old, are sparse [26] and may  require spe-
ial considerations for additional factors such as low birth weight
nd ambient air quality. Increasing amounts of RSV hospitaliza-
ion data are becoming available through inﬂuenza surveillance
ctivities, though case deﬁnitions may  need to be modiﬁed to
ave sufﬁcient sensitivity for detection of RSV cases, particularly
n young infants. Incidence rates vary widely across studies due to
ifferences in diagnostic methods, viral subtype, and co-infection
revalence. In addition, there are wide variations in the duration ofelopment (adapted from PATH RSV Vaccine Snapshot).
hospitalization among infants with RSV in different socio-economic
settings [27–29].
In 2010, there were an estimated 33 million global cases of
RSV-associated LRTI [26]. Although, this estimate was based on
community-based studies with active data, it was only from 24 data
points. Revised incidence estimates of severe RSV ALRI, based on
73 data points, are currently being calculated (Harish Nair, personal
communication). Dr. Nokes presented data from one community-
based cohort study in Kiliﬁ, Kenya [28,30], which used active
surveillance and set criteria for hospital referral as high respi-
ratory rate for age, as assessed by ﬁeld workers during weekly
home visits. The incidence rate of RSV-associated LRTI was  six-fold
higher when measured by active, compared to passive, surveillance
[28].
These ﬁndings suggest the incidence or duration of hospital-
ization due to RSV, used as a primary endpoint in RSV vaccine
trials and/or as a surrogate measure of severe disease would be
highly variable between settings for reasons unrelated to RSV
epidemiology. Furthermore, because many cases of RSV disease
do not present to the hospital, there was  general consensus
on a need for studies involving increased active surveillance or
facilitated passive surveillance, linked to community-based data
collection, to better inform trial design in LMICs. In addition,
background rates of potential adverse events need to be charac-
terized in areas where clinical trials of maternal vaccination are
planned for intrauterine fetal demise, congenital malformation,
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rematurity and intrauterine growth retardation. For trials of live
ttenuated pediatric vaccines, wheezing in infants should also be
onitored. Preparation for pivotal vaccine trials will require a
reparatory phase of data collection through longitudinal, epidemi-
logical studies with standardized case ascertainment. This will
etter inform trial design and result in more robust sample size
stimates.
. RSV vaccines in advanced clinical development
Representatives from industry presented the proﬁles of their
ost advanced RSV vaccine candidates and discussed target popu-
ations, clinical endpoints, trial designs, and safety measures. Dr.
llison August (Novavax) outlined the characteristics of the roset-
ed post-fusion subunit vaccine that has been shown, in phase II
rials, to elicit antibodies that inhibit Palivizumab binding in non-
regnant women of child-bearing age [31,32]. A phase II study to
ssess safety and immunogenicity in pregnant women is underway
nd a phase III trial of this vaccine candidate in pregnant women
s planned to start in the ﬁnal quarter of 2015. In this trial, women
ill be administered a single dose of the vaccine during the third
rimester of pregnancy, and their infants will be evaluated for inci-
ence of RSV-associated LRTI with hypoxemia (the decision is still
o be made on the oxygen saturation (SpO2) threshold) through the
rst six months of life. The minimal criteria for efﬁcacy and duration
f protection were stated to be 60% and 3 months, respectively.
Dr. Filip Dubovsky (MedImmune) described the company’s live-
ttenuated and live-vectored RSV vaccine program and gave an
pdate on the development [33–35] of their extended half-life
onoclonal antibody (MEDI8897), directed at the recently charac-
erized antigenic site Ø on pre-fusion F [12,13]. The live-attenuated
accines demonstrated shedding, generated a moderate level of
ntibody responses, and were not associated with enhanced dis-
ase. However, increased rates of LRTI that were observed among
ome vaccinees will require additional evaluation to understand
f this ﬁnding represents a true safety signal. As for prior vaccine
andidates, the efﬁcacy trial endpoints for MEDI8897 will include
SV-associated LRTI.
Although at an earlier stage of clinical development, passive pro-
hylaxis with the next-generation monoclonal MEDI8897 appears
igniﬁcantly superior to Palivizumab (a licensed monoclonal anti-
ody for the reduction of serious LRTI caused by RSV infection in
igh risk infants), with a 9-fold increase in in vivo potency and an
xtended half-life that could offer protection for several months
ollowing a single ﬁxed-dose intramuscular administration. Given
his potential for greater efﬁcacy, and planned tiered-pricing of the
roduct, a single birth dose of MEDI8897 may  ultimately prove
ost-effective for protection of infants in LMICs. However, the path-
ay to prequaliﬁcation for such a product would need to be created
e novo, as no monoclonal antibodies are currently prequaliﬁed by
he WHO.
Dr. Ilse Dieussaert (GlaxoSmithKline Biologicals) described two
arallel vaccine development pipelines for maternal and pediatric
opulations. Phase I data on an adjuvanted recombinant protein
ubunit intended for maternal vaccination showed no safety signals
nd moderate immunogenicity with higher neutralizing responses
han previous post-fusion F vaccine antigens. As phase III trials are
nvisioned, particular attention is being given to deﬁning the most
eliable and relevant efﬁcacy endpoints for different settings and
ge groups. Dr. Dieussaert provided a list of signs and symptoms for
eﬁning LRTI and severe LRTI that are currently being evaluated in
arge-scale epidemiologic studies in both high and low resource
ettings. Although each of the industry representatives proposed a
ist of possible endpoints for vaccine trials, there was  general agree-
ent that RSV-associated LRTI and severe LRTI, however they aree 34 (2016) 190–197 193
to be deﬁned, would be better primary outcome measures than
hospitalization (or death).
5. Regulatory considerations
Regulators from the US (Dr. Jeff Roberts, FDA Center for Biolo-
gics Evaluation and Research), UK (Dr. Mair Powell, Medicine and
Healthcare Products Registry), South Africa (Dr. James Southern),
and Ghana (Mr. Eric Karikari-Boateng) offered their perspectives on
the routes to RSV vaccine licensure. There was general agreement
that clinical efﬁcacy studies can feasibly be performed for RSV vac-
cines and would be required for licensure. In addition to reviewing
the quality, safety and efﬁcacy of the submitted product, regulatory
authorities will also have to consider speciﬁc RSV-related issues.
These include the necessity for increased vigilance for vaccine
enhanced disease in neonates and antigen-naïve infants, develop-
ment of a safety database for a ﬁrst-in-class vaccine to prevent
disease in infants through vaccination of pregnant women, and
possible use of different vaccine platforms for immunization of
pregnant women and young children for the same disease.
In phase III trials, regulatory agencies expect efﬁcacy endpoints
to reﬂect clinically relevant disease prevention, with veriﬁcation of
cases through both laboratory and clinical parameters. Although
the minimum number of vaccinees in pre-licensure studies for
an adequate safety database is not always prescribed, the num-
bers required for approval of recently licensed novel vaccines have
varied from about 6000 to over 40,000 (the latter in the case of
rotavirus vaccines, where theoretical safety signals drove the sam-
ple size) [36,37]. The prerequisites for a successful licensure or
marketing authorization approval will be addressed on a case-by-
case basis in discussion with the manufacturer.
6. Duration of follow-up
It was preferred that actively immunized infants should be
tracked through two RSV seasons to provide evidence of efﬁcacy,
cross-protection against multiple viral strains, and durability of
response. While vaccine efﬁcacy is expected to persist for 6 months
or less after passive immunization, extended follow-up could be
relevant for detection of unexpected adverse events in children
who were protected against severe RSV infection during their ﬁrst
season but experienced RSV infection during the second year of
life. Deferral of disease may  still provide substantial clinical bene-
ﬁt, as older infants are likely to be better able to mount a robust
immune response and recover more quickly, with likely lower
mortality and fewer long-term sequelae [38,39]. However, it is rec-
ommended that the frequency and severity of illness and pattern of
immune responses to infection be monitored during the next sea-
son. Extended follow up may  be considered in the post-marketing
surveillance periods, with a speciﬁc focus on the impact of immu-
nization on long term wheezing.
7. Geographical settings for clinical trials
Clinical efﬁcacy trials of RSV vaccine candidates are likely to be
conducted in both HICs and LMICs. Regulators from LMICs empha-
sized the need for efﬁcacy data relevant to low-resource settings
and the importance of deﬁning endpoints relevant to target popu-
lations. The oft-used endpoint in HICs of medically attended RSV
disease may  be less relevant in LMICs. For example, in some settings
a signiﬁcant proportion of children with acute respiratory symp-
toms may  not seek medical care or may  make their ﬁrst clinical
contact with a non-medical provider [40]. The choice of primary
endpoints in clinical trials will have to take account of the cultural
context in which the trials are being conducted. However, it will be
194 K. Modjarrad et al. / Vaccine 34 (2016) 190–197
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esirable to construct widely applicable endpoints with objective
linical criteria to deﬁne severe and very severe LRTI, and highly
peciﬁc validated PCR assays to conﬁrm RSV infection. Collabora-
ions between Northern and Southern hemisphere clinical trials
ites and harmonization of clinical endpoints will accelerate the
valuation of vaccines because of the complementary seasonality
f RSV infection.
. Clinical development pathway for maternal
mmunization
As a precaution and a legacy from the experiences of FI-RSV
nhanced disease, phase I trials that involve antigen-naïve infants,
n any age group or population, should occur in a setting with good
acilities for the management of adverse events. These facilities
hould have the capacity for vigilant follow-up throughout the RSV
eason and the availability of and access to ventilatory support.
or example, the ﬁrst trials could be conducted in HICs in North
merica, Europe or Australia followed by trials in lower resource
ettings. Thus, a staggered development pathway would allow for
he procession of trials in lower income settings soon after safety
ata emerge from higher resource settings.
There was general agreement among meeting participants
n the pathway to develop and license an RSV vaccine that
ould prevent RSV disease in infants less than 6 months of
ge through maternal immunization (Fig. 2). Novel vaccine can-
idates that meet preclinical criteria for use in human trials
hould ﬁrst be tested in trials that assess safety and immuno-
enicity in healthy adults, including non-pregnant women. Once
ata become available from these trials, the dose, schedule
nd administration route can then be selected from trials in
ealthy women in their third trimester of pregnancy. Addition-
lly, data will need to be collected on prematurity, intrauterine
etal demise, and other serious adverse perinatal outcomes. A
ingle dose vaccine is desirable, as multiple doses might be asso-
iated with decreased uptake. In any trial of pregnant women,
oth mother and infant should be followed for at least 6 months
ost-delivery, and preferably for longer into the second RSV sea-
on.One or more preliminary trials in pregnant women may  provide
ufﬁcient data to demonstrate transfer of functional maternal anti-
ody to the infant, persistence of maternal antibody, and overall
eduction of RSV disease in infants, but will not be powered tot pathway for pregnant women.
provide deﬁnitive estimates of vaccine efﬁcacy. These prelimi-
nary studies will therefore be used to inform the design of one
or more larger, conﬁrmatory vaccine efﬁcacy trials. It is also pos-
sible that once the dose, schedule and administration route have
been selected, preliminary and conﬁrmatory vaccine efﬁcacy data
could be obtained from the same trial based on predetermined
protocol-speciﬁed criteria, e.g. by incorporating an event-driven
interim analysis. These trials could also evaluate more than one reg-
imen – in the event of continued uncertainty regarding the optimal
dose or schedule – by using an adaptive trial design. In this case,
emphasis will be placed on the statistical procedures that govern
such an adaptive design.
Determination of vaccine efﬁcacy should be based on follow-up
of infants for at least 6 months or for as long as maternal antibody
has been documented to persist. Trials may  need to be carefully
timed such that the maternal vaccination period will result in births
coinciding with the early part of the RSV season. The follow up in
infants for safety is expected to be at least 12 months from delivery,
and at least 12 months from vaccination for safety in the mother,
and likely longer into the second RSV season. If timed appropriately,
it may  be possible to conduct more than one conﬁrmatory vaccine
efﬁcacy trial across multiple geographical settings. If low and high
income settings are merged into a single trial, thought should be
given to the design and implementation of case deﬁnitions, case
detection systems, endpoints, and study procedures that are appli-
cable to all trial settings. Furthermore, the estimated distribution of
cases contributing to key endpoints and differing cultural contexts
and community engagement procedures must be well understood
for each setting prior to trial initiation.
In general, the regulatory approach to the question of beneﬁt (or
lack thereof) in pregnant women  may  be driven by the desired indi-
cation sought by the manufacturer. If there is no claim of beneﬁt
to pregnant women, then there may  be no requirement to demon-
strate beneﬁt. For example, the language “prevention of RSV disease
in infants through vaccination of pregnant women” does not imply
any direct beneﬁt to the mother. However, sponsors are encouraged
to collect data on RSV incidence in vaccinated and unvaccinated
mothers as is feasible. Co-administration of vaccines is likely to
be an important issue as well, particularly in LMICs where fewer
antenatal visits mean fewer opportunities to vaccinate pregnant
women. In LMICs, tetanus vaccine is likely to be co-administered
with a licensed RSV vaccine, while TDaP and inﬂuenza vaccines are
more likely to be co-administered in HICs.
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Table  2
WHO  candidate case deﬁnitions for severe and very severe RSV associated lower respiratory tract infection (LRTI).
Severe RSV LRTI Very severe RSV LRTI
An infant or young child presenting to a health facility that is
part of the case ascertainment system for the phase III trial
who fulﬁlls both the laboratory AND clinical criteria below:
An infant or young child presenting to a health facility that is part of the case
ascertainment system for the phase III trial who fulﬁlls both the laboratory
AND clinical criteria below:
Laboratory criterion Laboratory criterion
RSV  infection as conﬁrmed by a ﬁt-for-purpose, fully
validated PCR assay with high speciﬁcity and sufﬁcient
sensitivity on upper respiratory samples
RSV infection as conﬁrmed by a ﬁt-for-purpose, fully validated PCR assay
with high speciﬁcity and sufﬁcient sensitivity on upper respiratory samples
Clinical criteria Clinical criteria
Respiratory infection deﬁned as cough or difﬁculty
breathing
Respiratory infection deﬁned as cough or difﬁculty breathing
AND  AND
LRTI deﬁned as fast breathing by WHO  criteria or
SpO2 < 95%
LRTI deﬁned as fast breathing by WHO  criteria OR  SpO2 < 95%
AND  AND
≥1  of the following features of severe disease ≥1 of the following features of very severe disease
–  Pulse oximetry < 93% – Pulse oximetry < 90%
–  Lower chest wall in-drawing – Inability to feed
– Failure to respond/unconscious
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mmunization
The approaches to the development of pediatric RSV vaccines
re more diverse than those to maternal RSV immunization. For
his reason, there was no consensus among meeting participants on
 speciﬁc framework for this target population. However, meeting
articipants generally agreed on an initial requirement for studies
f safety and immunogenicity in healthy adults. Safety data would
e expected from RSV-seropositive subjects before progressing to
he target population of seronegative infants. Additionally, it would
lso be necessary to assess safety and immunogenicity during co-
dministration with representative routine vaccines administered
o target age groups.
0. Clinical case deﬁnitions for RSV vaccine efﬁcacy trials
Meeting participants agreed that re-analyses of existing epi-
emiological data and initiation of new epidemiological studies
ill better inform the design of RSV vaccine trials. After consid-
ring case deﬁnitions proposed by different groups and ongoing
ork to update the WHO  pneumonia clinical management guide-
ines, consensus was achieved on candidate case deﬁnitions for
evere and very severe RSV-associated LRTI (Table 2). The case def-
nitions included clinical features considered to be objective, easily
tandardized, generalizable across settings, and generally accepted
arkers of severe or very severe RSV disease. Of note, these case
eﬁnitions rely heavily upon pulse oximetry. Thus, emphasis was
laced on the importance of using appropriate instruments and
tandardized methods for obtaining pulse oximetry readings. It was
roposed that these deﬁnitions be piloted in ongoing epidemiologic
nd surveillance studies, as well as in vaccine efﬁcacy trials. The
pidemiological studies could provide valuable information across
ettings on the sample size needed to demonstrate an effect against
evere and very severe RSV-associated LRTI.
1. Access for LMIC populations
For vaccine manufacturers the major economic market for RSV
accines is likely to be in HICs. Post-trial availability of the vaccine
n LMICs should be a requirement before RSV vaccine trials are
onducted. Stakeholders will have to ask and address the question
f when and how is it appropriate to test vaccines in LMICs and
hat assurances should be in place before such trials occur. Inthe case of malaria vaccines, it was deemed helpful to include
a “neutral party” who  would not stand to gain ﬁnancially if the
vaccine was  licensed. A product development partnership fulﬁlled
this role for a multi-site African phase III malaria vaccine trial.
These are important questions that were not fully addressed at
this meeting and merit further evaluation as the RSV vaccine ﬁeld
progresses.
The principle of global access to a safe and effective vaccine has
been a well-established principle of previous WHO  consultations.
Speciﬁcally, the WHO  will not condone a scenario where a vaccine
has been found to be safe and effective partly through testing in
LMIC settings but only becomes available in high-income markets.
Through the principle of equity, access to vaccines should be based
on public health need and not population income. Given that RSV
disease burden is disproportionately shifted toward LMICs, there
is a major onus on developers/funders to work towards ensuring
access, availability and affordability in these settings early in the
development and testing cycle.
12. Development of reference reagents for RSV vaccines
The majority of RSV vaccine development strategies aim to
elicit RSV-speciﬁc functional antibodies, as they have long been
associated with protection from RSV disease. There are nearly
a dozen different assays in use that measure virus neutralizing
antibodies, making it difﬁcult to directly compare immunogenicity
data across different vaccine candidates. Plaque reduction neutral-
ization (PRNT) is considered the gold standard, but it is a manual,
labor-intensive, and lengthy process not easily standardized across
laboratories. Microneutralization assays offer some improvement
in efﬁciency through higher throughput detection of viral infectiv-
ity. The addition of complement or the use of reporter viruses can
also increase assay sensitivity. Still, there is little consensus within
the RSV ﬁeld on what assays, and, more speciﬁcally, which method
to use and how to report results. Dr. Deborah Higgins (PATH)
described an effort by PATH, WHO, and the National Institute
for Biological Standards and Control to harmonize data across
various formats through the development of a series of clinical
assay reference reagents – available to product developers – to
facilitate evaluation and enable prioritization of early stage vaccine
candidates. The longer-term goal of this activity is to establish
one or more of these reagents as International Standards that are
applicable to a broad range of assays, enabling comparison of data
across studies, regardless of speciﬁc assay methodology.
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Table  3
List of consultation participants.
Name Organization Location
Participants
Narendra Kumar Arora The INCLEN Trust International New Delhi, India
Louis  Bont University Medical Center, Utrecht Utrecht, The Netherlands
Harry  Campbell Centre for Global Health Research Edinburgh, UK
Peter  Collins National Institutes of Health Bethesda, MD
Janet  Englund University of Washington Seattle, WA
Barney S. Graham National Institutes of Health Bethesda, MD
Eric  Karikari-Boateng Food and Drugs Authority Accra, Ghana
Ruth  Karron Johns Hopkins Bloomberg School of Public Health Baltimore, MD
David  Kaslow PATH Seattle, WA
Shabir  A. Madhi National Institute for Communicable Diseases Johannesburg, South Africa
Harish  Nair Centre for Global Health Research Edinburgh, UK
Patricia Njuguna KEMRI Wellcome Trust Kiliﬁ, Kenya
James Nokes KEMRI Wellcome Trust; Warwick University Kiliﬁ, Kenya; Coventry, UK
Fernando Polack Fundación INFANT Buenos Aires, Argentina
Mair  Powell Medicines and Healthcare Products Regulatory Agency London, UK
Nienke Scheltema Wilhelmina Children’s Hospital Utrecht, Netherlands
Claire-Anne Siegrist Centre Médical Universitaire Geneva, Switzerland
Eric  A.F. Simoes University of Colorado Health Sciences Center Denver, CO
Peter  Smith London School of Hygiene and Tropical Medicine London, UK
James  Southern Medicines Control Council Simon’s Town, South Africa
Observers
Allison  August Novavax Inc. Gaithersburg, MD
Ilse  Dieussaert GlaxoSmithKline Biologicals Wavre, Belgium
Filip  Dubovsky MedImmune Gaithersburg, MD
Amy  Fix Novavax Inc. Gaithersburg, MD
Jorge  Flores PATH Seattle, WA
Gregory Glenn Novavax Inc. Gaithersburg, MD
Pamela Grifﬁn MedImmune Gaithersburg, MD
Deborah Higgins PATH Seattle, WA
Keith  Paul Klugman The Bill & Melinda Gates Foundation Seattle, WA
Jean-Franc¸ ois Toussaint GlaxoSmithKline Biologicals Wavre, Belgium
Niteen  Wairagkar The Bill & Melinda Gates Foundation Seattle, WA
WHO  Secretariat
Ahmed Bellah HIS/RSS, WHO-HQ Geneva, Switzerland
Terry  Gail Besselaar HIP/HSE, WHO-HQ Geneva, Switzerland
Brigitte Giersing FWC/IVB, WHO-HQ Geneva, Switzerland
Ivana  Knezevic HIS/EMP, WHO  HQ Geneva, Switzerland
Kayvon Modjarrad FWC/IVB, WHO  HQ Geneva, Switzerland
Vasee  Moorthy FWC/IVB, WHO  HQ Geneva, Switzerland
Wenqing Zhang HIP/HSE, WHO-HQ Geneva, Switzerland
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3. The concept of an RSV vaccine roadmap
Dr. David Kaslow (PATH) outlined the critical role of the malaria
accine technology roadmap in prioritizing activities for research,
roduct development, capacity building, policy and commercializa-
ion for the purpose of achieving licensure, recommendation and
ptake of malaria vaccines. This process has been and continues to
e instrumental in establishing a shared vision and strategic goals
hrough consultation with multiple stakeholders, and is reviewed
very 5 years or sooner if new data become available that change
trategic thinking. The WHO  proposed that a similar process be
stablished to identify gaps in the product development pathway
or RSV vaccines, to meet the two agreed strategic goals, namely a
accine for maternal/passive immunization to prevent RSV disease
n those under 6 months, and a vaccine for pediatric immunization
o prevent RSV disease in infants and young children. This will be
rafted through consultation of an RSV Roadmap Working Group,
ill provide guidance rather than a prescription of the way  forward,
nd is anticipated to be available by mid-2016.
4. ConclusionsThere are about ten RSV vaccine candidates currently in clin-
cal trials and several dozen in pre-clinical development (Fig. 2).
fter several decades of addressing major challenges in vaccineGeneva, Switzerland
design and development, the RSV vaccine ﬁeld is poised to enter
a new phase involving late stage testing of more than one vaccine
approach. As RSV disease burden and mortality disproportionately
affect infants and young children living in LMICs, actions need to
be taken now to ensure pivotal phase III efﬁcacy trials include
key populations and endpoints that are relevant to developing
countries. An initial step toward clinical development of RSV vac-
cines for global use was  achieved through this WHO  consultation.
Representatives from higher and lower income countries (Table 3)
convened and agreed upon two target populations for vaccine test-
ing and use (pregnant women and young children), the general
principles of a clinical development pathway for these two  popu-
lations (Fig. 2), and candidate case deﬁnitions for severe and very
severe RSV disease (Table 2).
As more vaccine candidates enter clinical development and
efﬁcacy trials, it will be the task of regulators, researchers, manufac-
turers, and governmental bodies to further reﬁne the agreements
and deﬁnitions that were discussed at this meeting and to develop
population-speciﬁc information to optimize vaccine safety, efﬁ-
cacy, and implementation feasibility. To provide guidance toward
those ends, the WHO  is creating working groups to develop a pre-
ferred product characteristics document (to guide target product
proﬁles) and a vaccine roadmap. These guides will offer a more
detailed vision of the path forward for an RSV vaccine that is
intended for global use.
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